Adeza Likely To Use IPO Proceeds To Enlarge Preterm Birth Test Indication
This article was originally published in The Gray Sheet
Executive Summary
Adeza Biomedical may use a portion of the $69 mil. it expects to generate from an initial public offering to expand the U.S. indication for its Fetal Fibronectin Test to women at "low-risk" of giving birth preterm